Skip to content
ClinCalc Pro
Menu
Antiemetic Pregnancy: SPC section 4.6, verbatim: 'Women of childbearing potential should consider the use of contraception. ... Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy. In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)). The available epidemiological studies on cardiac malformations show conflicting results. Animal studies does not indicate direct or indirect harmful effects with respect to reproductive toxicity. Ondansetron should not be used during the first trimester of pregnancy.' Breast-feeding: 'Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving Ondansetron should not breast-feed their babies.' Fertility: 'There is no information on the effects of ondansetron on human fertility.'

Ondansetron

Brand names: Zofran, Ondansetron 4mg

Ondansetron is a 5-HT3 receptor antagonist antiemetic used to prevent and treat post-operative nausea and vomiting and nausea and vomiting associated with chemotherapy and radiotherapy.

Adult dose

Dose: Chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV), adults, ORAL: 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, then 8 mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis. For HIGHLY emetogenic chemotherapy a single oral dose of up to 24 mg taken with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used; oral treatment is then continued at 8 mg twice daily for up to 5 days after the course. Prevention of POST-OPERATIVE nausea and vomiting (PONV), adults, ORAL: 16 mg taken one hour prior to anaesthesia. SCOPE: these are ORAL adult doses only. The same source states that ondansetron 'can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration' and that intravenous or intramuscular administration is recommended for the TREATMENT of established PONV, but it gives no adult intravenous, intramuscular or rectal milligram dose — verify any injectable or rectal dose against the SPC of that presentation.
Route: Oral (4 mg per 5 ml syrup). SPC posology, closing line, verbatim: 'Method of administration Oral'.
Frequency: CINV/RINV: one dose 1 to 2 hours before treatment, then every 12 hours, for a maximum of 5 days. PONV prevention: a single dose one hour prior to anaesthesia.
Max: 32 mg total over 24 hours, given as DIVIDED doses. Quoted from the SPC posology section, footnote (b) to the chemotherapy dosing tables and repeated in the surrounding text, verbatim: 'The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.' This is a 24-hour total in divided doses — no single 32 mg dose is authorised anywhere in this source. A lower ceiling applies in hepatic impairment (see hepaticAdjustment).
The recovered UK product is an oral ondansetron syrup whose licensed indications — CINV/RINV and PONV — are the page's primary indications, so the indication matches and only the route is a subset; that scope is stated inside the dose text above, as required. No figure has been taken from the US label. || VERBATIM (SPC posology, emetogenic chemotherapy and radiotherapy, adults): 'Ondansetron can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration. For oral administration: 8mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis. For highly emetogenic chemotherapy): a single dose of up to 24mg ondansetron taken with 12mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Ondansetron should be continued for up to 5 days after a course of treatment. The recommended dose for oral administration is 8mg twice daily.' || VERBATIM (PONV, adults): 'For the prevention of PONV: Ondansetron can be administered orally or by intravenous or intramuscular injection. For oral administration: 16mg one hour prior to anaesthesia. For the treatment of established PONV: Intravenous or intramuscular administration is recommended.' — note that the source gives no milligram figure for that injectable treatment dose in adults. || ELDERLY, verbatim: 'Ondansetron is well tolerated by patients over 65 years. No alteration of oral dose or frequency of administration is required.' POOR SPARTEINE/DEBRISOQUINE METABOLISERS, verbatim: 'No alteration of daily dosage or frequency of dosing are required.' || PAEDIATRIC — paedDose is deliberately left null. The source does carry paediatric figures, but they are INTRAVENOUS and differ by indication, so storing one of them as a per-kg value alongside this page's oral syrup would misrepresent both route and strength in the weight calculator. Recorded here verbatim for a later, route-specific pass. CINV in children aged 6 months and over and adolescents, by BSA: 'Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m 2 . The intravenous dose must not exceed 8 mg. Oral dosing can commence twelve hours later and may be continued for up to 5 days' — BSA < 0.6 m2: 5 mg/m2 IV plus 2 mg syrup after 12 hrs, then 2 mg syrup every 12 hours; BSA 0.6 to 1.2 m2: 5 mg/m2 IV plus 4 mg syrup or tablet after 12 hrs, then 4 mg every 12 hrs; BSA > 1.2 m2: 5 mg/m2 or 8 mg IV plus 8 mg syrup or tablet after 12 hours, then 8 mg every 12 hours. CINV by bodyweight: 'Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals' — 10 kg or under: up to 3 doses of 0.15 mg/kg every 4 hours then 2 mg syrup every 12 hours; over 10 kg: up to 3 doses of 0.15 mg/kg every 4 hours then 4 mg syrup or tablet every 12 hours. In every band 'The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg', and section 4.4 warns that 'when calculating the dose on an mg/kg basis and administering three doses at 4-hourly intervals, the total daily dose will be higher than if one single dose of 5mg/m 2 followed by an oral dose is given'. PONV in children aged 1 month and over and adolescents: 'a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1mg/kg up to a maximum of 4mg either prior to, at or after induction of anaesthesia', and the same dose may be used for treatment after surgery; 'No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting'. 'There are no data on the use of ondansetron in the treatment of PONV in children below 2 years of age.' In paediatric clinical studies ondansetron was 'given by IV infusion diluted in 25 to 50 mL of saline or other compatible infusion fluid and infused over not less than 15 minutes'. || NOT IN THIS BUNDLE: no adult intravenous or intramuscular milligram dose, no rectal/suppository posology, and no posology for hyperemesis gravidarum, gastroenteritis or palliative-care nausea. Some sections of the product information we used were incomplete — check the full SPC.

Dose adjustments

Renal

SPC posology, verbatim: 'Patients with Renal impairment: No alteration of daily dosage or frequency of dosing, or route of administration are required.'

Hepatic

SPC posology, verbatim: 'Patients with Hepatic impairment: Clearance of Ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8mg should not be exceeded.'

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. Corresponding doses of ondansetron tablets may be used interchangeably. Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and Vomiting Indication Dosage Regimen Highly Emetogenic Cancer Chemotherapy A single 24 mg dose administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-04-24. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients
  • Concomitant use with apomorphine
  • NOT listed as a contraindication in this SPC but a section 4.4 instruction — 'Avoid ondansetron in patients with congenital QT syndrome.'
  • Excipient caution — this syrup contains sodium benzoate (E211), 'which may increase jaundice (yellowing of the skin and eyes) in new born babies (up to 4 weeks old)', and xylitol (E967), which may have a laxative effect

Side effects

  • Very common: headache
  • Common: sensation of warmth or flushing; constipation
  • Uncommon: seizures; movement disorders including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia; arrhythmias; chest pain with or without ST segment depression; bradycardia; hypotension; hiccups; asymptomatic increases in liver function tests
  • Rare: immediate hypersensitivity reactions, sometimes severe, including anaphylaxis; QTc prolongation including Torsades de Pointes; dizziness during rapid IV administration; transient visual disturbances such as blurred vision, predominantly during IV administration
  • Very rare: transient blindness predominantly during intravenous administration — 'The majority of the blindness cases reported resolved within 20 minutes.'
  • Frequency unknown: myocardial ischaemia — 'In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron.'
  • Post-marketing: serotonin syndrome (altered mental status, autonomic instability, neuromuscular abnormalities) with concomitant serotonergic drugs including SSRIs and SNRIs
  • 'The adverse event profiles in children and adolescents were comparable to that seen in adults.'

Monitoring

  • QT interval and cardiac risk — section 4.4: ondansetron prolongs the QT interval in a dose-dependent manner and post-marketing Torsades de Pointes has been reported; administer with caution to patients who have or may develop QTc prolongation, including those with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, or taking other medicinal products that prolong QT or cause electrolyte abnormalities.
  • 'Hypokalemia and hypomagnesaemia should be corrected prior to ondansetron administration.'
  • Alert patients to the signs and symptoms of myocardial ischaemia.
  • Monitor patients with signs of subacute intestinal obstruction after administration, as ondansetron increases large bowel transit time.
  • After adenotonsillar surgery, follow patients carefully — 'prevention of nausea and vomiting with ondansetron may mask occult bleeding'.
  • Observe the patient appropriately if a serotonergic drug is clinically warranted alongside ondansetron.
  • Watch for respiratory events and treat them symptomatically — section 4.4 notes clinicians should 'pay particular attention to them as precursors of hypersensitivity reactions'; hypersensitivity has occurred in patients who reacted to other selective 5HT3 receptor antagonists.
  • Paediatric: 'Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.'

Clinical monograph

How it works

It selectively blocks 5-HT3 (serotonin) receptors peripherally on vagal afferents and centrally in the chemoreceptor trigger zone, interrupting the emetic reflex.

Prescribing in practice

  • It prolongs the QT interval, so observe dose limits and use with caution or avoid alongside other QT-prolonging drugs or uncorrected electrolyte disturbance.
  • Constipation and headache are common adverse effects.
  • In pregnancy (for example hyperemesis gravidarum) use only after weighing risks and benefits, as first-trimester use has been associated with a small increase in the risk of cleft palate.

Monitoring

Consider ECG and check electrolytes (including potassium and magnesium) in patients at risk of QT prolongation, and monitor bowel function.

Counselling the patient

  • This medicine can cause constipation and headache — let us know if these become troublesome.
  • Tell your doctor about any heart rhythm problems or other medicines you take, as some can affect your heartbeat.
  • Seek urgent help if you notice palpitations, fainting or an irregular heartbeat.

Evidence & guidelines

Widely guideline-recommended for chemotherapy-induced and post-operative nausea and vomiting; MHRA advice on QT prolongation and first-trimester use.

Reference: NICE; MHRA Ondansetron Safety Update 2013; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.